Skip to main content

Advertisement

Fig. 2 | Cell & Bioscience

Fig. 2

From: miR-7 methylation as a biomarker to predict poor survival in early-stage non-small cell lung cancer patients

Fig. 2

Kaplan–Meier survival curves for early-stage NSCLC in relation to miR-7 methylation. X-axis displays the number of months from diagnosis to progression (a, b) or death (c). Y-axis: Probability of PFS (a, b) or OS (c). a Kaplan–Meier survival curve for PFS for MPC cohort (n = 42). The data showed a trend toward increased progression in those with methylated miR-7, but not statistically significant (p = 0.297). b Kaplan–Meier survival curve for PFS for TCGA cohort (n = 795). The PFS of patients with methylated miR-7 was significantly lower (p = 0.010, HR = 0.696). c Kaplan–Meier survival curve for OS for TCGA cohort (n = 879). The graph showed a trend toward increased mortality in miR-7 methylated group. Methylated mirR-7 demonstrated a significantly shorter survival when compared to the patients with unmethylated miR-7 (p = 0.007, HR = 0.894)

Back to article page